Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response
dc.contributor.author | Katz, Lior | en_US |
dc.contributor.author | Gisbert, Javier P. | en_US |
dc.contributor.author | Manoogian, Beth | en_US |
dc.contributor.author | Lin, Kirk | en_US |
dc.contributor.author | Steenholdt, Casper | en_US |
dc.contributor.author | Mantzaris, Gerassimos J. | en_US |
dc.contributor.author | Atreja, Ashish | en_US |
dc.contributor.author | Ron, Yulia | en_US |
dc.contributor.author | Swaminath, Arun | en_US |
dc.contributor.author | Shah, Somal | en_US |
dc.contributor.author | Hart, Ailsa | en_US |
dc.contributor.author | Lakatos, Peter Laszlo | en_US |
dc.contributor.author | Ellul, Pierre | en_US |
dc.contributor.author | Israeli, Eran | en_US |
dc.contributor.author | Svendsen, Mads Naundrup | en_US |
dc.contributor.author | van der Woude, C. Janneke | en_US |
dc.contributor.author | Katsanos, Konstantinos H. | en_US |
dc.contributor.author | Yun, Laura | en_US |
dc.contributor.author | Tsianos, Epameinondas V. | en_US |
dc.contributor.author | Nathan, Torben | en_US |
dc.contributor.author | Abreu, Maria | en_US |
dc.contributor.author | Dotan, Iris | en_US |
dc.contributor.author | Lashner, Bret | en_US |
dc.contributor.author | Brynskov′, Jorn | en_US |
dc.contributor.author | Terdiman, Jonathan P. | en_US |
dc.contributor.author | Higgins, Peter D.R | en_US |
dc.contributor.author | Chaparro, Maria | en_US |
dc.contributor.author | Ben‐horin, Shomron | en_US |
dc.date.accessioned | 2012-11-07T17:04:23Z | |
dc.date.available | 2014-01-07T14:51:07Z | en_US |
dc.date.issued | 2012-11 | en_US |
dc.identifier.citation | Katz, Lior; Gisbert, Javier P.; Manoogian, Beth; Lin, Kirk; Steenholdt, Casper; Mantzaris, Gerassimos J.; Atreja, Ashish; Ron, Yulia; Swaminath, Arun; Shah, Somal; Hart, Ailsa; Lakatos, Peter Laszlo; Ellul, Pierre; Israeli, Eran; Svendsen, Mads Naundrup; van der Woude, C. Janneke; Katsanos, Konstantinos H.; Yun, Laura; Tsianos, Epameinondas V.; Nathan, Torben; Abreu, Maria; Dotan, Iris; Lashner, Bret; Brynskov′, Jorn ; Terdiman, Jonathan P.; Higgins, Peter D.R; Chaparro, Maria; Ben‐horin, Shomron (2012). "Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response ." Inflammatory Bowel Diseases 18(11): 2026-2033. <http://hdl.handle.net/2027.42/94222> | en_US |
dc.identifier.issn | 1078-0998 | en_US |
dc.identifier.issn | 1536-4844 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/94222 | |
dc.description.abstract | Background: Intensifying infliximab therapy is often practiced in Crohn's disease (CD) patients losing response to the drug but there are no data if halving the interval is superior to doubling the dose. We aimed to assess the efficacy of infliximab dose intensification by interval‐halving compared with dose‐doubling. Methods: A multicenter retrospective study of CD patients losing response to infliximab was undertaken. The clinical outcome of patients whose infusion intervals were halved (5 mg/kg/4 weeks) was compared with patients treated by dose‐doubling (10 mg/kg/8 weeks). Results: In all, 168 patients were included from 18 centers in Europe, USA, and Israel. Of these, 112 were intensified by dose‐doubling and 56 received interval‐halving strategy. Early response to dose‐escalation was experienced by 86/112 (77%) patients in the dose‐doubling group compared with 37/56 patients (66%) in the interval‐halving group (odds ratio [OR] 1.7, 95% confidence interval [CI] 0.8–3.4, P = 0.14). Sustained clinical response at 12 months postescalation was maintained in 50% of patients in the dose‐doubling group compared with 39% in the interval‐halving group (OR 1.5, 95% CI 0.8–2.9, P = 0.2). On multivariate analysis, predictors of long‐term response to escalation were a nonsmoking status, CD diagnosis between 16–40 years of age, and normal C‐reactive protein (CRP). Conclusions: Dose intensification leads to a sustained regained response in 47% of CD patients who lost response to standard infliximab dose, but halving the infusion intervals is probably not superior to dose‐doubling. Given the costs and patient inconvenience incurred by an additional infusion visit, the dose‐doubling strategy may be preferable to the interval‐halving strategy. (Inflamm Bowel Dis 2012;) | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Crohn's Disease | en_US |
dc.subject.other | Infliximab | en_US |
dc.subject.other | Inflammatory Bowel Disease | en_US |
dc.title | Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical Center, Ann Arbor, USA | en_US |
dc.contributor.affiliationother | 1st Department of Medicine, Semmelweis University, Budapest, Hungary | en_US |
dc.contributor.affiliationother | Gastroenterology Department, Sheba Medical Center, Tel Hashomer, Tel‐Aviv University, Israel | en_US |
dc.contributor.affiliationother | Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain | en_US |
dc.contributor.affiliationother | Division of Gastroenterology, Department of Medicine, University of California San Francisco, San Francisco, USA | en_US |
dc.contributor.affiliationother | Department of Medical Gastroenterology, Herlev Hospital, University of Copenhagen, Denmark | en_US |
dc.contributor.affiliationother | 1st Department of Gastroenterology, Evangelismos Hospital, Athens, Greece | en_US |
dc.contributor.affiliationother | Center for Inflammatory Bowel Disease at Cleveland Clinic, Digestive Diseases Institute in Cleveland, Ohio, USA | en_US |
dc.contributor.affiliationother | Division of Gastroenterology, Tel‐Aviv Medical Center, Israel | en_US |
dc.contributor.affiliationother | Division of Gastroenterology, Columbia university Presbyterian hospital, New‐York, New‐York, USA | en_US |
dc.contributor.affiliationother | University of Miami Miller School of Medicine, Miami, Florida, USA | en_US |
dc.contributor.affiliationother | St. Marks Hospital, London, United Kingdom | en_US |
dc.contributor.affiliationother | Gastroenterology Department, Mater Dei Hospital, Msida, Malta | en_US |
dc.contributor.affiliationother | Gastroenterology Department, Hadassah Medical Center, Jerusalem, Israel | en_US |
dc.contributor.affiliationother | Medicinsk afdeling Vejle, Sygehus Hospital, Denmark | en_US |
dc.contributor.affiliationother | Erasmus Medical Center, Rotterdam The Netherlands | en_US |
dc.contributor.affiliationother | Hepato‐Gastroenterology Unit, 1st Department of Internal Medicine, Medical School of Ioannina, Ionnina, Greece | en_US |
dc.contributor.affiliationother | Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA | en_US |
dc.contributor.affiliationother | Gastroenterology Department, Sheba Medical Center, Tel Hashomer 52621, Israel | en_US |
dc.identifier.pmid | 22294554 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/94222/1/22902_ftp.pdf | |
dc.identifier.doi | 10.1002/ibd.22902 | en_US |
dc.identifier.source | Inflammatory Bowel Diseases | en_US |
dc.identifier.citedreference | Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462 – 2476 | en_US |
dc.identifier.citedreference | Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005; 128: 862 – 869. | en_US |
dc.identifier.citedreference | Hanauer S, Feagan B, Lichtenshtein G, et al. Maintenance infliximab for Crohn's disease: the ACCENT 1 randomized trial. Lancet. 2002; 359: 1541 – 1549. | en_US |
dc.identifier.citedreference | Pariente B, Pineton de Chambrun G, Desroches M, et al. Clinical value of measuring trough levels and human anti‐chimeric antibodies in patients with inflammatory bowel disease who lost response to infliximab therapy. J Crohn Colitis. 2011; 5: S111 – 112. | en_US |
dc.identifier.citedreference | Afif W, Loftus EV, Faubion WA, et al. Clinical utility of measuring Infliximab and human anti‐chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010; 105: 1133 – 1139. | en_US |
dc.identifier.citedreference | Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007; 56: 1226 – 1231. | en_US |
dc.identifier.citedreference | Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long‐term efficacy of Infliximab in Crohn's disease. N Engl J Med. 2003; 348: 601 – 608. | en_US |
dc.identifier.citedreference | Ben‐Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab lies within the Fab fragment, but measurement of antibodies against the intact Infliximab molecule shows superior clinical usefulness. Gut. 2011; 60: 41 – 48. | en_US |
dc.identifier.citedreference | Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost‐effectiveness analysis. Aliment Pharmacol Ther. 2007; 26: 1509 – 1520. | en_US |
dc.identifier.citedreference | Sandborn WJ, Abreu MT, D'Haens G, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol. 2010; 8: 688 – 695. | en_US |
dc.identifier.citedreference | Sandborn WJ, Colombel JF, Schreiber S, et al. Dosage adjustment during long‐term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis. 2011; 17: 141 – 151. | en_US |
dc.identifier.citedreference | Requeiro M, Siemanowski B, Kip K, et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis. 2007; 13: 1093 – 1099. | en_US |
dc.identifier.citedreference | Schnitzler F, Fidder H, Ferrante M, et al. Long‐term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single‐centre cohort. Gut. 2009; 58: 492 – 500. | en_US |
dc.identifier.citedreference | Kopylov U, Mantzaris GJ, Katsanos KH, et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of Infliximab. Aliment Pharmacol Ther. 2011; 33: 349 – 357. | en_US |
dc.identifier.citedreference | St. Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Arthritis Rheum. 2002; 46: 1451 – 1459. | en_US |
dc.identifier.citedreference | Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009; 104: 760 – 767. | en_US |
dc.identifier.citedreference | Ben‐Horin S, Chowers Y. Review article: loss of response to anti‐TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011; 33: 987 – 995. | en_US |
dc.identifier.citedreference | Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004; 2: 542 – 553. | en_US |
dc.identifier.citedreference | Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004; 126: 402 – 413. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.